KPRX
Kiora Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.55
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 16.0M | — | — |
| Cost of Revenue | 42.0K | 24.8K | — | — | — |
| Gross Profit | (42.0K) | (24.8K) | 16.0M | — | — |
| Operating Expenses | |||||
| R&D Expense | 6.4M | 10.8M | 4.9M | 4.0M | 3.4M |
| SG&A Expense | 5.9M | 5.7M | 5.5M | 4.7M | 8.3M |
| General & Admin Expense | 5.9M | 5.7M | 5.5M | 4.7M | 8.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 436.8K | (7.1M) | 1.1M | 3.9M | 582.6K |
| Total Operating Expenses | 12.8M | 9.4M | 11.5M | 12.6M | 12.3M |
| Cost and Expenses | 12.8M | 9.5M | 11.5M | 12.6M | 12.3M |
| Operating Income (EBIT) | (12.8M) | (9.5M) | 4.5M | (12.6M) | (12.3M) |
| Non-Operating | |||||
| Interest Income | 677.7K | 894.0K | 1.3M | 174.0K | 56.9K |
| Interest Expense | — | 20.0K | 21.4K | 11.1K | 8.6K |
| Net Interest Income | 677.7K | 874.0K | 1.2M | 162.9K | 48.3K |
| Other Non-Op Income/Expense | 541.3K | (2.7M) | 1.1M | 163.3K | (1.4M) |
| Non-Operating Income (excl Interest) | (540.3K) | 2.6M | (1.2M) | (174.5K) | 1.4M |
| EBT (Pre-Tax Income) | (12.3M) | (12.1M) | 5.7M | (12.4M) | (13.7M) |
| Income Tax Expense | (1.3M) | (1.3M) | 2.1M | 90.3K | (113.0K) |
| Bottom Line | |||||
| Net Income | (11.0M) | (10.8M) | 3.6M | (12.5M) | (13.6M) |
| Earnings from Cont. Ops | (11.0M) | (10.8M) | 3.6M | (12.5M) | (13.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.0M) | (10.8M) | 3.6M | (13.0M) | (13.6M) |
| Per Share | |||||
| Basic EPS | ($2.50) | ($2.64) | $0.93 | ($24.25) | ($18.55) |
| Diluted EPS | ($2.50) | ($2.64) | $0.87 | ($24.25) | ($18.55) |
| Revenue Per Share | $0.00 | $0.00 | $4.13 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.2M | 4.1M | 3.9M | 538007 | 732303 |
| Diluted Shares Outstanding | 6.2M | 4.1M | 4.1M | 538007 | 732303 |
| Profitability Metrics | |||||
| EBITDA | (12.2M) | (12.1M) | 5.7M | (12.4M) | (13.6M) |
| D&A | 63.0K | 24.8K | 19.2K | 51.8K | 41.6K |
| EBIT | (12.3M) | (12.1M) | 5.7M | (12.4M) | (13.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026